GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Adagene
Adagene is a biotech company developing innovative antibody-based drugs for the treatment of cancer. Its stock price is highly volatile, driven by news about clinical trials and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Pharma immune
Adagene is a biotech company developing innovative antibody-based immunotherapies for cancer treatment using its proprietary platform. We classify it as an "Immune Pharmaceutical." The chart below illustrates the overall dynamics of this cutting-edge segment.
Broad Market Index - GURU.Markets
Adagene is an oncology company developing antibody-based drugs for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Adagene shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ADAG - Daily change in the company's share price Adagene
For Adagene, an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas for innovative biotech companies.
Daily change in the price of a set of shares in a market segment - Pharma immune
Adagene Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ADAG's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Adagene is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Adagene
Adagene Inc.'s year-over-year performance is the story of its smart antibody platform. Its 12-month market cap depends on progress in clinical trials of its immuno-oncology drugs, as well as partnerships with major pharmaceutical companies that license its technology to create a new generation of targeted and safe drugs.
Annual dynamics of market capitalization of the market segment - Pharma immune
Adagene Inc. is a clinical-stage biotech developing immunotherapy for cancer. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adagene is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Adagene
Adagene is a clinical-stage biotech developing antibodies for cancer immunotherapy. Its monthly performance is driven by progress in its research and partnerships. Positive data on its drugs or news of collaborations with major pharma companies drives its valuation up.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Adagene is a clinical-stage biotech company developing innovative antibodies for cancer immunotherapy. Its NEObody platform enables the creation of drugs that target difficult-to-reach targets. The graph below illustrates the dynamics of the biotech sector, where technology platforms are key to the creation of new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adagene is a clinical-stage biotech. Its shares don't follow the market, but rather move abruptly following the release of trial data or partnership news. The chart shows monthly dynamics, which reflect investors' faith in science rather than the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Adagene
Adagene, a clinical-stage biotech developing antibody-based immunotherapeutics, is experiencing high volatility. Weekly stock performance is driven by clinical trial data and partnerships with major pharmaceutical companies, reflecting the risks and promises in immuno-oncology.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Adagene is a biotech company developing antibodies for cancer immunotherapy. The chart compares its volatile, news-driven performance with the overall sector. This helps us understand whether the stock's price surges are a reaction to unique scientific findings or to general industry sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Adagene is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that ADAGENE's performance is largely uncorrelated with the market, moving based on its own unique news rather than general trends.
Market capitalization of the company, segment and market as a whole
ADAG - Market capitalization of the company Adagene
Adagene's stock price is a financial bet on a new generation of antibodies for cancer treatment. This biotech company's market cap reflects its hopes for its technological platform, which enables the creation of "smart" antibodies targeting tumors. Its dynamics are a barometer of its clinical progress and partnerships with global pharmaceutical giants.
ADAG - Share of the company's market capitalization Adagene within the market segment - Pharma immune
Adagene's market share in immuno-oncology reflects its technological strength. The company is developing a new generation of antibodies to fight cancer. Its market share is determined not by current sales, but by the value of its advanced drug development platform and partnerships with pharmaceutical giants.
Market capitalization of the market segment - Pharma immune
Adagene is a biotech company developing antibody-based immunotherapy drugs. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect investor hopes for breakthroughs in cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. Its market capitalization reflects the potential of its scientific platform. The chart below shows the economic weight of early-stage cancer drug development companies.
Book value capitalization of the company, segment and market as a whole
ADAG - Book value capitalization of the company Adagene
For Adagene, an oncology company, book value is its equity and its advanced antibody technology platform. The chart below shows its financial resources for science. This level is an indicator of the company's ability to fund its numerous R&D programs.
ADAG - Share of the company's book capitalization Adagene within the market segment - Pharma immune
Adagene is a clinical-stage biotech company developing antibodies for cancer immunotherapy. Its value lies in its scientific platform and patents. Its share of tangible assets will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma immune
Adagene is a clinical-stage biotech company. Its value is created in the laboratories where innovative antibodies are developed. This is a "light" model, based on science. The chart below shows how much the pharmaceutical industry as a whole relies on tangible assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Adagene's balance sheet is a technology platform for the creation and development of innovative antibodies for cancer immunotherapy. The company's assets represent capital invested in science that enables the creation of safer and more effective drugs. The chart illustrates the scale of this investment in the future of oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Adagene
Adagene is a biotech company developing antibodies for cancer immunotherapy. Its balance sheet is funded by R&D. Its market capitalization reflects the potential of its technology platform to create safe and effective drugs. The chart shows how the market values its scientific approach and partnerships with major pharmaceutical companies.
Market to book capitalization ratio in a market segment - Pharma immune
Adagene is a biotech company developing antibodies for cancer immunotherapy. Its value lies in its scientific platform and patents. This chart clearly demonstrates how the market valuation based on the potential of its technology far exceeds the value of its lab equipment.
Market to book capitalization ratio for the market as a whole
Adagene is a biotech company developing innovative antibodies for cancer treatment. The chart shows how the market values its unique technology platform. Adagene's market capitalization is based not on its labs, but on the potential of its scientific approach to create more effective and safer oncology drugs, which is what attracts investors.
Debts of the company, segment and market as a whole
ADAG - Company debts Adagene
Adagene is a clinical-stage biotech focused on immuno-oncology. For a company whose products have not yet reached the market, debt instruments can serve as a bridge to funding costly clinical trials. This chart shows how Adagene manages its resources to advance its research.
Market segment debts - Pharma immune
Adagene is a clinical-stage biotech company specializing in cancer immunotherapy. Their platform enables the creation of antibodies against complex targets. The chart illustrates the financial climate for the biotech sector, which is driving Adagene, like many of its peers, to raise capital from investors to fund their long-term and expensive research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Adagene
Adagene is a biotech company developing a new generation of immuno-oncology drugs. Its survival and success depend on its ability to fund lengthy and expensive R&D. This chart shows the company's debt level, allowing investors to assess the financial risk the company is taking in pursuit of scientific breakthroughs in cancer treatment.
Market segment debt to market segment book capitalization - Pharma immune
Developing next-generation antibodies for cancer immunotherapy, like Adagene's, requires significant scientific and financial investment. This chart shows how the biotech sector as a whole funds its R&D. It allows us to assess how Adagene's financial model, with its unique technology platform, differs from other players in this highly competitive market.
Debt to book value of all companies in the market
Adagene is developing a new generation of immuno-oncology drugs. Like many research-stage biotech companies, Adagene may use debt to finance clinical trials. This chart provides context, showing how its financial liabilities compare to the overall debt level in the market, which includes debt-free giants.
P/E of the company, segment and market as a whole
P/E - Adagene
This chart shows the valuation of Adagene, a clinical-stage biopharmaceutical company specializing in immuno-oncology. For a company without stable revenue, its value is determined by the potential of its antibody research platform. The chart reflects investors' faith in its technology and future commercial success.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Adagene operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Adagene is a biotech company developing antibodies for cancer immunotherapy using its proprietary technology platform. Its valuation depends on the validation of this platform through clinical trials. This chart shows the overall interest in oncology and allows us to assess whether the market sees Adagene's technology as a real advantage over competitors in this crowded but promising field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Adagene
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy using its unique platform. The company's future depends on the success of its clinical programs and partnerships with major pharmaceutical companies. This chart shows how investors view the potential of its technology to create safer and more effective cancer drugs.
%20P%2FE%20Adagene&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Adagene&v=1772581411426 "Chart of the company's future (projected) P/E Adagene")
Future (projected) P/E of the market segment - Pharma immune
Adagene is a biotech company developing antibodies for cancer immunotherapy. The company's unique platform allows for the creation of antibodies with novel properties and for complex targets. This chart reflects expectations for the biotech sector, helping to assess how highly the market values this innovative scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772581411448 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. Their platform enables the development of next-generation therapeutics. This graph of overall expectations reflects investor sentiment toward cutting-edge science. Market optimism and risk appetite are critical for Adagene to attract funding for research and development of its unique therapeutic approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772581411583 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Adagene
Adagene is a clinical-stage biotechnology company developing innovative antibodies for cancer immunotherapy. This chart shows the cost of developing next-generation drugs. Revenue depends on the success of clinical trials and partnerships with major pharmaceutical companies for further development and commercialization.
Profit of companies in the market segment - Pharma immune
Tempest Therapeutics is a clinical-stage oncology company developing combination therapy. Its financial future depends on the results of its trials. This chart reflects the state of the biotech sector, where investor expectations and potential value are based not on current revenue but on the scientific potential to change the standard of cancer treatment.
Overall market profit
Adagene is a biotech company developing innovative antibodies for the treatment of cancer. Like other companies in clinical development, its value is determined by the potential of its scientific platform. It is an example of a business that can radically change its trajectory after successful trials, regardless of the overall economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Adagene
Adagene is a biotech company developing innovative antibody-based immuno-oncology therapies. Its revenue forecast is entirely dependent on the success of clinical trials and potential partnerships with major pharmaceutical companies. This chart reflects analyst expectations for Adagene's scientific platform and its ability to develop new cancer treatments.
%20profit%20of%20the%20company%20Adagene&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Adagene&v=1772581411837 "Graph of future (projected) profit of the company Adagene")
Future (predicted) profit of companies in the market segment - Pharma immune
Adagene is a biotech company developing antibodies for cancer immunotherapy. Its unique platform enables the creation of drugs that target difficult-to-reach targets. This chart shows profitability projections for the oncology sector. It reflects the overall hopes for a breakthrough in cancer treatment and allows one to assess the potential of Adagene's innovative approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772581412027 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Adagene is a biotech company developing immunotherapeutic drugs for cancer treatment. Its success depends on scientific breakthroughs, but funding research requires capital. The overall corporate earnings forecast, illustrated by this chart, influences investor sentiment and their willingness to invest in high-risk but promising biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772581412203 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Adagene
Adagene is a biotech company developing antibodies for cancer immunotherapy using its unique platform. Currently in the clinical stage, its revenue is generated through partnerships. The chart shows how the market values the potential value of its technology platform and pipeline of future drug candidates, rather than current revenue.
P/S market segment - Pharma immune
Adagene Inc. is a clinical-stage biopharmaceutical company developing innovative antibodies for cancer immunotherapy using its proprietary technology platform. This chart shows the average valuation in the sector, allowing one to assess how the market perceives the revenue potential of Adagene's unique scientific foundation.
P/S of the market as a whole
Adagene is a biotech company developing antibodies for cancer immunotherapy using its proprietary AI platform. The company's valuation is based on the potential of its technology platform. This chart, reflecting the average real revenue estimate for the market, clearly highlights how biotech investments are betting on scientific breakthroughs rather than current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Adagene
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. This chart shows how investors assess the future potential of its scientific platform. This assessment is based on expectations of successful clinical trials and partnerships with major pharmaceutical companies for commercialization.
%20P%2FS%20Adagene&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Adagene&v=1772581412263 "The graph of the company's future (projected) P/S Adagene")
Future (projected) P/S of the market segment - Pharma immune
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. Its platform enables the creation of drugs that target difficult-to-reach targets. The chart shows how the market assesses Adagene's future sales potential compared to other biotechs, reflecting confidence in its unique technology and scientific advancements.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772581412316 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This chart reflects investor confidence in new antibody technologies. Adagene, with its platform for developing masked antibodies that activate only in tumors, aims to make immunotherapy safer and more effective. Their innovative approach demonstrates how science is finding ways to improve existing cancer treatments, which supports optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772581412374 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Adagene
Adagene is a clinical-stage biopharmaceutical company specializing in the development of innovative antibodies for cancer immunotherapy. Currently, its revenue is generated not from sales but from upfront and milestone payments from strategic partners. This chart illustrates the progress of its research and the attractiveness of its technology platform.
Sales of companies in the market segment - Pharma immune
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. Its platform enables the development of drugs that precisely target tumors while minimizing side effects. This chart reflects overall revenue in the immunology pharmaceutical sector. It highlights a huge and growing market in which Adagene is competing with its cutting-edge technology.
Overall market sales
Adagene is a clinical-stage biotechnology company developing innovative antibodies for cancer immunotherapy. Its platform enables the creation of antibodies with unique properties. The company's future depends on the results of clinical trials. This overall economic activity pattern influences the overall investment climate in the biotech sector and investors' risk appetite.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Adagene
Adagene is a biotech company developing antibodies for cancer immunotherapy using its proprietary platform. Its future depends on the success of clinical trials and partnerships with major pharmaceutical companies. The chart shows analysts' speculative revenue forecasts, which are betting on a breakthrough in oncology treatment.
%20sales%20of%20the%20company%20Adagene&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Adagene&v=1772581412525 "Schedule of future (projected) sales of the company Adagene")
Future (projected) sales of companies in the market segment - Pharma immune
Adagene is a biotech company developing antibodies for cancer immunotherapy. Its platform enables the creation of drugs that target difficult-to-reach targets and offer enhanced safety. This chart reflects projected sales for the entire immunotherapy pharmaceutical segment, highlighting overall growth expectations for this cutting-edge field in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772581412554 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Adagene is a clinical-stage biotech company focused on immuno-oncology. Its platform enables the creation of innovative antibodies to fight cancer. This overall economic activity schedule impacts the availability of funding for the biotech sector, which is critical for conducting lengthy and expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772581412568 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Adagene
Adagene is a biotechnology company developing innovative antibodies for cancer immunotherapy. This metric reflects its financial progress through the clinical development stage. It demonstrates the level of investment in research and testing required to bring the next generation of drugs to market and achieve future commercial success.
Market segment marginality - Pharma immune
Adagene is a clinical-stage biotech developing antibodies for cancer immunotherapy. Its financial performance reflects intensive investment in R&D. This chart helps evaluate the company's operational structure and level of investment in its scientific platform compared to other companies in the immuno-oncology field.
Market marginality as a whole
Adagene is a clinical-stage biotech developing innovative antibodies for cancer immunotherapy. Their unique platform enables the creation of drugs with high precision and safety. Their future depends on the results of their studies. This overall profitability curve is influenced solely by the general availability of venture capital in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Adagene
Adagene is a clinical-stage biotech company focused on immuno-oncology and the development of innovative antibodies. Its primary resource is its scientific talent. This chart shows how the company is growing its research team to advance several drug candidates through complex and costly clinical trials.
Share of the company's employees Adagene within the market segment - Pharma immune
Adagene is a biotech company developing innovative antibodies for cancer immunotherapy. This chart shows the percentage of scientists the company employs in the fields of antibody engineering and immuno-oncology. Its team is developing a new generation of drugs designed to make the immune system smarter in its fight against tumors.
Number of employees in the market segment - Pharma immune
Adagene Inc. is a clinical-stage biotechnology company developing innovative antibodies for cancer immunotherapy. This chart shows overall employment in the immunology research sector. It illustrates how rapidly this field is developing and highlights the competition for scientists and investment in the development of next-generation cancer drugs.
Number of employees in the market as a whole
Adagene is a biotech company creating innovative antibodies for cancer immunotherapy using its proprietary artificial intelligence platform. It represents the synergy of biotechnology and IT. This graph reflects the labor market, where new specialties are emerging at the intersection of sciences. Adagene is creating demand not only for biologists but also for machine learning and data analysis specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Adagene (ADAG)
Adagene Inc. is a biotech company developing innovative antibody-based cancer immunotherapy. This chart is a classic example of biotech. The extremely high market capitalization per employee suggests that the market is valuing not the company's current operations, but rather the scientific platform and patent portfolio developed by a highly qualified but relatively small team.
%20of%20the%20company%20Adagene%20(ADAG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Adagene-ADAG&v=1772581412933 "Chart of market capitalization per employee (in thousands of dollars) of the company Adagene (ADAG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Adagene is a biotech company developing antibody-based immuno-oncology therapies. Their key asset is their proprietary technology platform. This metric reflects how highly the market values their scientific potential. The higher the metric, the more investors believe their unique technology will lead to future blockbusters.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772581413016 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Adagene Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer. Its valuation is determined by the potential of its technology platform and pipeline of candidates. Its high capitalization per employee is typical for biotech, where intellectual capital is valued far more than physical assets.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772581413029 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Adagene (ADAG)
Adagene is a clinical-stage biotech company developing a new generation of antibodies for cancer immunotherapy. It is a 100% R&D business. This metric reflects their capital burn rate—the net loss (research costs) per highly qualified scientist working on their platform.
%20Chart%20Adagene%20(ADAG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Adagene-ADAG&v=1772581413047 "Company Profit Per Employee (in thousands of dollars) Chart Adagene (ADAG)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Adagene is a clinical-stage biotech company developing innovative antibodies for cancer treatment. As with other R&D firms, this timeline is a goal for the future. Currently, all value lies in the intellectual potential of their scientific team. A successful drug will allow them to generate profit per employee that will significantly exceed the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772581413178 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Adagene (ADAG) is a biotech company developing innovative antibodies for cancer immunotherapy using a proprietary platform. Their business is focused on deep scientific research. This chart shows the economics of their R&D. Until their drugs are licensed or sold, each scientist contributes a loss to their income statement.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772581413210 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Adagene (ADAG)
For Adagene, a biotech company developing immuno-oncology drugs, this chart shows the performance of its scientific platform. Revenue per employee is likely generated through partnerships with major pharmaceutical companies, and its growth depends on the success of clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Adagene-ADAG&v=1772581413222 "Sales chart per company employee Adagene (ADAG)")
Sales per employee in the market segment - Pharma immune
Adagene is a clinical-stage biopharmaceutical company developing innovative antibody-based cancer treatments. This R&D metric reflects average revenue per employee by segment. It allows us to assess how productive Adagene's scientific team is in advancing its candidates compared to other immuno-oncology biotechs.
Sales per employee for the market as a whole
Adagene (ADAG) is a clinical-stage biopharmaceutical company developing innovative cancer immunotherapy. Currently, its staff consists entirely of researchers. This metric is critical for ADAG: it's at zero. Future growth will depend on either successful licensing of their platform or receiving partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company Adagene (ADAG)
Adagene is a clinical-stage biotech developing antibodies for cancer immunotherapy. It operates in one of the most competitive fields in medicine. This chart reflects investor bets that its technology will fail to differentiate itself from existing giants (such as Keytruda) and will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Adagene-ADAG&v=1772581413321 "Short Shares Chart for the Company Adagene (ADAG)")
Shares shorted by market segment - Pharma immune
Adagene (ADAG) is a biopharmaceutical company focused on immuno-oncology and the development of innovative antibodies. This chart summarizes the bearish bets on the immuno-oncology biotech sector. It shows the overall market pessimism regarding the high level of competition and the failure rate in developing next-generation cancer treatments.
Shares shorted by the overall market
Adagene (ADAG) is a clinical-stage biotech. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Adagene (ADAG)
Adagene is a biotech company (immuno-oncology), whose R&D platform creates unique antibodies. This chart measures the level of speculative hope. It shows when the stock is "overheated" (overbought) on positive R&D news or "oversold" amid a general cooling in the sector or geopolitical risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Adagene-ADAG&v=1772581413356 "RSI 14 indicator chart for the company's stock Adagene (ADAG)")
RSI 14 Market Segment - Pharma immune
Adagene (ADAG) is a biotech (China/USA) that engineers antibodies. Their platform (NEObody) creates masked (hidden) antibodies that are activated only inside the tumor. The Pharma-immune (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ADAG's growth due to their R&D, or is the entire biotech industry "overheated"?
RSI 14 for the overall market
Adagene (ADAG) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADAG (Adagene)
Adagene is a biopharmaceutical company using its AI platform (NEObody) to create innovative antibodies (including "masked" antibodies) for cancer immunotherapy. This chart shows the speculative average price target from analysts based on their belief in this technology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADAG-Adagene&v=1772581413405 "A chart showing analyst consensus forecasts for the expected stock price. ADAG (Adagene)")
The difference between the consensus estimate and the actual stock price ADAG (Adagene)
Adagene is a biotech company developing a new generation of "smart" antibodies (SAFEbody technology) for cancer immunotherapy. This chart measures the gap between the current price and the consensus target price. It shows whether experts believe this innovative scientific platform can create future blockbusters.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADAG-Adagene&v=1772581413450 "A chart showing the difference between the consensus forecast and the actual stock price. ADAG (Adagene)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Adagene is a biotech company using AI to develop innovative antibodies (NEObodies) for cancer immunotherapy. This chart shows analysts' overall expectations for the entire immunopharma sector. It reflects whether experts believe AI can accelerate oncology R&D or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Adagene is a Chinese biotech company developing a platform for creating innovative antibodies (immunotherapy) for cancer treatment. This chart shows overall risk appetite. For Adagene, operating in a high-risk sector and in a geopolitically sensitive jurisdiction (China), overall market optimism is important, but investors weigh it against the specific risks of the region.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Adagene
Adagene is a clinical-stage biotech focused on immuno-oncology. Their signature feature is cloaked antibodies (NEObody technology), which are activated only within the tumor, reducing side effects. This graph represents pure R&D betting. Its valuation reflects the market's faith in their unique scientific platform and the data from their early (and very risky) clinical trials.
AKIMA Market Segment Index - Pharma immune
Adagene is a biotech company developing a new generation of antibody-based immuno-oncology therapies using its NEObody platform. This chart shows the average index for the immuno-pharma sector. It provides investors with a benchmark for how Adagene, which is developing breakthrough technology, compares to the industry average.
The AKIM Index for the overall market
Adagene is a biotech company using an AI-powered platform to create antibodies (cancer immunotherapy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative early-stage scientific story, which combines technology and biology, compares to overall economic trends and investor interest in biotech.
